L-692585 is a potent and nonpeptidylgrowth hormone secretagogue receptor (GHS-R1a)agonist, with aK_iof 0.8 nM. L-692585 acts directly on somatotropes causing GH release^[1][2].

Ki: 0.8 nM (GHS-R1a)^[1]

L-692585 (10 μM; 2 min) produces a prompt transient increase in [Ca²⁺]_i, following by the sustained decline to a plateau above the basal level in GH cells^[2].
L-692585 (0.01-10 μM; 2 min) induces release of growth hormone (GH) in a dose-dependent manner from isolated porcine somatotropes^[2].
L-692585 (100 nM) significantly increases the number and size of plaques, and it also causes a significant increase in total secretion index (TSI)^[2].

L-692585 (0.01-0.1 mg/kg; i.v. once daily for 2 weeks) increases peak plasma GH levels and total GH release^[3].
L-692585 (0.005-0.1 mg/kg; a single i.v.) significantly increases peak GH concentrations 4.3-fold at a dose of 0.005 mg/kg, 7-fold at a dose of 0.02 mg/kg, and 21-fold at a dose of 0.10 mg/kg in vivo^[3].

567.68

C₃₂H₃₇N₇O₃

145455-35-2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.